Abstract. The interactions between exogenously added tissue-type plasminogen activator (t-PA) and the active form of type 1 plasminogen activator inhibitor (PAl-l) produced by and present in cultured human umbilical vein endothelial cells (HUVECs) were investigated. Immunoblotting analysis of the conditioned media obtained from monolayers of HUVECs treated with increasing concentrations of t-PA (~<10/zg/ml) revealed a dose-dependent formation of both t-PA/PAI-1 complexes, and of a 42,000-M, cleaved or modified form of the inhibitor. Immunoradiometric assays indicated that t-PA treatment resulted in a fourfold increase in PAI-1 antigen present in the conditioned media. This increase did not result from the release of PAI-1 from intracellular stores, but rather reflected a t-PAdependent decrease in the PAI-1 content of the Triton X-100 insoluble extracellular matrix (ECM). Although the rate of t-PA-mediated release of PAI-1 was increased by the removal of the monolayer, similar quantities of PAI-I were removed in the presence or absence of the cells. These results suggest that the cells only represent a semipermeable barrier between ECMassociated PAI-1 and exogenous t-PA. Treatment of HUVECs with t-PA (1 /xg/ml, 2 h) to deplete the ECM of PAI-1 did not affect the subsequent rate of PAI-1 production and deposition into the ECM. Immunogold electron microscopy of HUVECs not only confirmed the location of PAI-1 primarily in the region between the culture substratum and the ventral cell surface but failed to demonstrate significant (<1%) PAI-1 on the cell surface. Thus, the majority of PAId associated with cultured HUVEC monolayers is present under the cells in the ECM and is accessible to solution-phase t-PA.
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Although four molecules with PAI activity have been detected, the endothelial cell-derived inhibitor (PAI-1) (Sprengers and Kluft, 1987; Loskutoff et al., 1988) appears to be 1. Abbreviations used in this paper: CM, conditioned medium; ECM, extracellular matrix; IRMA, immunoradiometric assay; HUVECs, human umbilical vein endothelial cells; PA, plasminogen activator; PAl, plasminogen activator inhibitor; PAId, type 1 plasminogen activator inhibitor; t-PA, tissue-type plasminogen activator. the physiologic inhibitor of tissue-type plasminogen inhibitor (t-PA). PAI-I is a member of the serine proteinase inhibitor (Serpin) superfamily (Carrel and Travis, 1985; Ny et al., 1986 , Pannekoek et al., 1986 and differs from other PAls in its stability to SDS (van Mourik et al., 1984; Hekman and Loskutoff, 1985) , its electrophoretic mobility (Erickson et al., 1986) , and its ability to inhibit single-chain t-PA (Colucci et al., 1986; Hekman and Loskutoff, 1988) . In addition, PAI-1 is synthesized as an active molecule but is unstable in solution and rapidly decays into a latent, inactive form at 37°C (Levin, 1986; Kooistra et al., 1986) . Active PAI-1 appears to be stabilized through its binding to other proteins . For example, PAI-1 has been detected in the extracellular matrix (ECM) of a variety of cultured cells (Laiho et al., 1986; Levin and Santell, 1987; Knudsen et al., 1987; Mimuro et al., 1987; Rheinwald et al., 1987; Pollanen et al., 1987; Knudsen and Nachman, 1988) and shown to be active (Levin and Santell, 1987; Mimuro et al., 1987, Knudsen and Nachman, 1988) . The binding of PAI-1 to the ECM protects it from the spontaneous inactivation that occurs in solution, increasing its apparent half-life from <3 h to >24 h (Mimuro et al., 1987) . The binding protein in the ECM may be vitronectin (Mimuro and Loskutoff, 1989a,b) . Active PAId in plasma is also detected in a complex with another molecule (Wiman et al., 1988) shown to be vitronectin (DeClerk et al., 1988) .
The observation that t-PA is able to bind to and form complexes with the PAL1 associated with confluent human umbilical vein endothelial cells (HUVECs) has led to the concept that active PAI-1 is also present on the surface of these cells (Barnathan et al., 1988; Sakata et al., 1988) . However, accurate interpretation of these results may be hindered by the large amounts of PAId present in the ECM of these cells, especially if it is accessible to t-PA. In this report, we have studied the interaction between exogenous t-PA and the PAL1 associated with intact cultured HUVECs. We show that the majority of this PAI-1 is present under the cells in the ECM and that it is accessible to solution-phase t-PA. Immunogold electron microscopy revealed that <1% of the PAI-1 was present on the dorsal cell surface of these cells.
Materials and Methods

Reagents
Reagents were obtained as follows: FCS, trypsin, penicillin, and streptomycin from Gibco Laboratories ( 
Fibrinolytic Proteins
t-PA was purified from human melanoma cell-conditioned medium, and its activity was determined by the ~25I-fibrin plate assay as described previously . The final product had a specific activity of ,x,500,000 U/mg of protein when compared with the t-PA International Standard and consisted primarily (>90%) of the single-chain form. The t-PA International Standard (83/517) and the urokinase International Standard (66/46) were kindly supplied by the National Institute for Biological Standards and Controls (London, Great Britain). Goat antiserum to t-PA was obtained from Bio-Pool (Hornefors, Sweden), and the immunoglobulin G fraction was prepared as described previously (Schleef et ai., 1985) .
Human PAId was purified from the media conditioned by a transformed human lung fibroblast cell line (SVdo WI38 VAI3 2RA) according to procedures described previously (Hekman and Loskutoff, 1988) . PAId was isolated primarily in a latent form and was activated by treatment with 4 M guanidine-hydrochloride (1 h, 37°C) followed by dialysis against PBS at 4°C Loskutoff, 1985, 1988) . PAId activity was quantitated by measuring its ability to inhibit t-PA mediated lysis of ~25I-labeled fibrin (Schleef et al., 1988b) . 1 U of PAId is defined as the amount required to inhibit the activity of 2 IU of t-PA by 50%. Antiserum to purified PAI-1 was raised in both New Zealand rabbits and White Lewis rats (Breeding Colony, Research Institute of Scripps Clinic) according to standard procedures. Rabbit antibodies to PAId were affinity purified using human PAId bound to cyanogen bromide-activated Sepharose 4B.
Growth and Treatment of HUVECs
HUVECs were isolated from 2-5 freshly collected umbilical cords, pooled, and grown in culture dishes coated with purified fibronectin (1 #g/cm2). The growth medium consisted of M199 with 20% FCS, and was supplemented with endothelial cell growth factor (ECGF; 75 #g/ml), porcine intestinal beparin (90 #g/ml), and antibiotics (Schleef et al., 1988a) . For experimental use, HUVECs were grown to confluency in 24-well Costar culture plates (Corning Science Products) and maintained at confluency for 3 d before use. To prepare conditioned media (CM), the monolayers were washed with 0.5 ml of serum-free M199 and then incubaaxl in the presence or absence of t-PA (0-10 #g/ml) for up to 8 h in M199. The CM was centrifuged (10,000 g, 10 min, 4°C) and stored at -20°C until used. Cell lysates were prepared by washing the monolayers with cold PBS (0.01 M sodium phosphate, 0.14 M NaCI, pH 7.4) and extracting the cellular components for 10 min at 37°C with 0.5 ml of PBS containing 0.5% Triton X-100. The lysates were removed and stored at -20°C until used. ECM was prepared by washing Triton X-100 extracted plates three times with distilled water to remove remaining cellular components. Light microscopic examination for the presence of cellular debris indicated that this extraction procedure completely removed visible cellular components from the culture dishes (Mimuro et al., 1987) . ECM bound to the culture dishes was solubilized by the addition of 0.5 ml of SDS sample buffer.
Immunoradiometric Assays (IRMAs)
t-PA/PAI-1 complexes were measured in a two-site IRMA as described previously (Mimuro et al., 1987; Hekman and Loskutoff, 1988) . Briefly, samples were diluted in IRMA buffer (PBS supplemented with 3% BSA, 5 mM EDTA, 0.1% Tween 80, and 0.02% NAN3) and incubated for 1.5 h at 37°C in microtiter wells precoated with goat anti-t-PA (50 #l/well, l0 #g/ml). Plates were blocked with 3% BSA and after each incubation step, washed with PBS containing 0.1% BSA, 0.05% NAN3, and 0.05% Tween 80. Bound PAId was quantitated radiometrically after incubating the washed wells first with rabbit anti-PAl-I, and then with tESl-labeled goat anti-rabbit IgG (105 cpm/well). The wells were individually removed, and the radioactivity in each was determined. PAId antigen was quantitated by a similar two-site IRMA. In this case, affinity-purified rabbit antibodies to human PAId (5 #g/ ml in PBS) were coated onto microtiter wells (4°C for 16 h). After blocking the wells with 3% BSA and washing, test samples or purified PAl-I, diluted in IRMA buffer, were incubated in the antibody-coated wells at 37°C for 1.5 h. Bound PAL1 was quantitated radiometrically by incubating the washed wells first with rat antiserum to human PALl and then with 1251-labeled goat anti-rat IgG.
Quantitation of ECM-associated PAl4
PAId antigen associated with the Triton Xd00-insoluble ECM was quantitared immunologically either directly on the plate (Mimuro et al., 1987) or by solubilizing the ECM into SDS sample buffer and analyzing the samples by immunoblotting (described below). To quantitate ECM PAId directly on 96-well microtiter plates, the ECM were incubated (4°C, I h) with M199 supplemented with 5 mg/ml normal goat IgG (MI99-IgG) to block nonspecific IgG binding sites. The wells were then incubated (1 h, 37°C) with a primary antibody (10/zg/ml of either affinity-purified rabbit anti-PAid or of normal rabbit IgG) diluted in M199-IgG. The plates were washed and the bound antibodies were detected with t25I-goat anti-rabbit IgG (2 x 105 cpm/100 #1). After washing the wells with M199, the ECM was solubilized into SDS sample buffer and the radioactivity in each well was determined in a gamma counter.
Immunoblotting
The relative molecular mass species of PAI-1 amigen in the various samples was assessed by immunoblotting as described previously (Schleef et al., 1988a) . Samples were first subjected to discontinuous SDS-PAGE (Laemmli, 1970) , and then the proteins were electrophoretically transferred (50 V, 1.5 h) to nitrocellulose using a buffer containing 50 mM Tris base, 95 mM glycine, 20% methanol, and 0.01% SDS (Towbin et al., 1979) . The nitrocellulose sheets were soaked in PBS containing 1% casein (PBS/casein) for 1 h at room temperature to block additional protein binding sites and then were incubated overnight at 4°C in PBS/casein containing rabbit antiserum to human PAId (1:500 dilution). The nitrocellulose sheets were washed three times (10 min each wash) with PBS/easein and then incubated for 2 h at room temperature with ~2SI-labeled goat anti-rabbit lgG (250,000 cpm/ml). After washing, the nitrocellulose sheets were dried and exposed to XAR x-ray film for 24-48 h at -70"C.
Immunoelectron Microscopy
HUVEC monolayers in 24-well Costar plates were incubated (4°C, I h) with MI99-IgG to block nonspecific IgG binding sites. The cells were then incubated (1 h, 4°C) with a primary antibody (10 #g/ml of either affinitypurified rabbit anti-PAI-1 or normal rabbit lgG) diluted in MI99-IgG. The cells were washed and incubated (4°C, 1 h) with 10-mm-diam goldconjugated goat anti-rabbit IgG (Janssen Life Sciences Products, Piscataway, NJ) diluted in MI99-IgG. After washing the monolayers with M199, the cells were stored in cold Karnovsky's fixation buffer (1.5% glutaraldehyde, 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.4) until processed. The cells were briefly rinsed with PBS, postfixed with 1.5% OsO4 in 0.1 M cacodylate buffer, pH 7.2, for 1 h at room temperature, and dehydrated in a graded ethanol series. The wells were flat embedded in Epon 812 and after polymerization, stained en block with uranyl acetate.
To quantify the amount of anti-PAI-1 specific gold particles bound to the cell surface or culture substratum, four strips of 3 x 8 mm from each group were cut out from the Epon sheet containing cell monolayers. Two such strips from the same group were sandwiched together, cells apposed, with fresh Epon. Sections from these sandwiched blocks bearing two layers of cells were cut perpendicular to the culture substratum, double stained with uranyl acetate and lead citrate, and mounted on 100-mesh parallel lined grids (Ted Pelta, Inc., Tustin, CA) so that both cell layers ran longitudinally between two grid bars. Quantification of gold particles on nucleated cells was carried out at 15,000x on a Hitachi 12-UA electron microscope. Only one section from each block was used for quantitative analysis. A total of eight blocks containing 16 different areas of cells was examined in each group. The density of gold markers is expressed as the number of particles per 25 nucleated cells from a representative section.
Miscellaneous
protein concentration was determined by the method of Bradford (1976) . Antibodies were enzymatically labeled with t25I by using solid-state lactoperoxidase-glucose oxidase reagents and carrier-free Na 1251. The 12~I-labeled goat anti-rabbit IgG had a specific activity of 2-5 × 106 cpm/tzg protein.
did not affect H U V E C morphology or viability as indicated by staining with trypan blue. Furthermore, incubation of H U V E C monolayers with t-PA diluted in either serum-free media supplemented with 1% BSA/ECGF/heparin or in 20%
R e s u l t s Effect of t-PA on the Distribution of PAI-1 in HUVECs
The interactions between exogenously added t-PA and endogenous PAI-1 associated with intact H U V E C monolayers were initially assessed by irnmunoblotting analysis. As several other investigators have reported (Kooistra et al., 1986; Barnathan et al., 1988; Sakata et al., 1988) , the addition of t-PA to H U V E C s in vitro resulted in the formation of t-PA/PAI-1 complexes of 100,000 Mr in the C M , and of a cleaved or modified form of PAI-1 of 42,000 M, (Fig. 1, A) . Neither the size nor the relative amount of PAI-1 antigen present in cell lysates (i.e., the Triton X-100-soluble fraction) of H U V E C s was affected by t-PA treatment (Fig. 1 B) . In contrast, t-PA caused a dose-dependent decrease in the PAI-1 content of the Triton X-100-insoluble E C M (Fig. 1 C) . Approximately 10-20% of the total PAI-1 remained associated with the E C M even at the highest t-PA concentrations. This PAI-1 appeared to be resistant to t-PA since neither modified PAI-1 nor t-PA/PAI-1 complexes could be detected in the E C M by immunoblotting. Phase-contrast microscopic examination indicated that the H U V E C monolayers exhibited a normal cobblestone morphology in serum-free conditions for short periods of incubation, t-PA-treatment (<10 #g/ml) Figure 1 . Immunoblotting analysis for PAI-I in HUVECs treated with t-PA. Confluent monolayers were incubated (1 h, 37°C) in serum-free media supplemented with the indicated concentrations of t-PA (lane 1, 0; lane 2, 0.01 #g/ml; lane 3, 0.1 #tg/ml; lane 4, 1 #g/ ml; lane 5, 2 #g/ml, lane 6, 10/~g/ml). The CM were removed and the cells were lysed with 0.25% Triton X-100. After washing, the Triton X-100-insoluble ECM remaining on the plate was solubilized in SDS sample buffer. Samples (100 #1 aliquots corrresponding to 4 × 104 cells) of CM (A), cell lysates (B), and ECM (C) were fractionated by SDS-PAGE, electrophoretically transferred to nitrocellulose, and analyzed by immunoblotting using rabbit anti-PAI-1 followed by J25I-goat anti-rabbit IgG. The results show the dried nitrocellulose sheets exposed to XAR x-ray film for 48 h. Positions of relative molecular mass standards are indicated.
Figure 2. PAI-I antigen present in ECM prepared by removing
HUVECs with Triton X-100 or EDTA. Confluent monolayers were incubated with media alone (lanes I and 2) or with media supplemented with 10 #g/ml t-PA (lanes 3 and 4). After l h at 37°C, the monolayers were washed and ECM were prepared either by removing the cells by lysis with 0.25% Triton X-100 (lanes 1 and 3) or by detaching the cells with l0 mM EDTA (lanes 2 and 4). The resulting ECM preparations were washed three times with distilled water and extracted into SDS sample buffer. Samples (100 #l aliquots corresponding to 4 x 104 cells) were fractionated by SDS-PAGE, electrophoretically transferred to nitrocellulose, and analyzed with rabbit anti-PAid followed by 125I-goat anti-rabbit IgG.
The dried nitrocellulose was exposed to XAR x-ray film for 24 h. Positions of relative molecular mass standards are indicated. serum-containing growth media supplemented with 2 U/ml Trasylol resulted in t-PA/PAI-1 complex formation and depletion of PAI-1 from the ECM comparable to the data in Fig.  1 (data not shown) .
A number of intracellular proteins are known to remain associated with the ECM after the extraction of cultured cells with detergents (Avnur and Geiger, 1981; Carter and Hakomori, 1981) . To determine whether Triton X-100-insoluble intracellular proteins were the source of ECM PAId, we also prepared ECM by removing the ceils intact with the divalent cation chelator, EDTA. Fig. 2 demonstrates that approximately equivalent amounts of PAI-I were present in ECM prepared by either Triton X-100 treatment (Fig. 2, lane 1) or by detaching the cells intact with EDTA (lane 2). Furthermore, treatment of HUVEC monolayers with t-PA (10 #g/ml) removes the majority of the PAI-1 present in the ECM, independent of whether the cells were subsequently removed by treatment with Triton X-100 (Fig. 2, lane 3) or with EDTA (lane 4).
To quantitate the amount of complexes that are formed during the interaction of t-PA with HUVECs, a two-site IRMA was used. Control HUVECs secrete t-PA at a constant rate of "00.25 ng/h per llY cells and this t-PA forms complexes with endogenously released PAId (Fig. 3 A) . In contrast to these results, when exogenous t-PA is added to the cultures, there is an initial rapid rate of complex formation which is then followed by a slower more linear second phase (Fig. 3 A) . Analysis of these samples in a two-site IRMA for PAI-1 antigen (Fig. 3 B) revealed a corresponding rapid, t-PA mediated increase in the inhibitor, followed by a second slower rate of PAI-1 accumulation. The initial rapid increase is again in contrast to the slower, relatively constant linear release of PAI-1 into the CM of untreated HUVECs which occurs at ,08 ng/h per 1@ cells.
Ultrastructural Localization of PAI-1
Immunoelectron microscopy was used to more precisely localize the PAI-1 that is associated with intact HUVEC monolayers and is accessible to exogenous t-PA. Analysis of cross sections of nonpermeabilized HUVECs stained first with rabbit antibodies to PAId and then with gold-conjugated goat anti-rabbit IgG revealed the presence of PAI-1 antigen primarily between the culture substratum and the underlying Confluent HUVEC monolayers were incubated (1 h, 370C) in M199 in the presence or absence of 5 ~g/ml t-PA. The cells were washed and incubated (1 h, 4°C) with 10 /zg/ml of affinity-purified rabbit antibodies to PAI-I or nonimmune rabbit lgG followed by gold-conjugated goat anti-rabbit lgG. The cells were fixed and processed for transmission electron microscopy as described in Materials and Methods. Data shown are from a representative section and expressed as the total number of immunogold particles detected on the dorsal and ventral cell surfaces of 25 cells displaying nuclei, representing 800-1,000 ~M of linear culture substratum surface.
ventral cell membrane (Fig. 4 A) . Quantitation of the total gold particles distributed over 25 nucleated cell lengths (,x,800-1,000 #M linear length) confirmed the presence of PAI-1 beneath the ventral cell surface (Table I) , and demonstrated that <1% of the total gold particles were present on the dorsal cell surface membrane. Incubation of HUVECs with t-PA (5/~g/ ml; 1 h, 37°C) before immunoelectron microscopic localization of PAI-1 significantly decreased the number of gold particles detected both beneath the monolayers (Fig. 4 B ; Table  I ), and on the dorsal cell surface (Table I ). In control experiments, few gold particles were detected in cross sections of HUVECs that were incubated with normal rabbit IgG followed by gold-conjugated goat anti-rabbit IgG (Fig. 4 C; Table I).
Kinetics of the Interaction between t-PA and ECM-associated PAI-I
The above observations indicate that the majority of HUVECassociated PAI-1 is present in the ECM. Moreover, the PAI-1 in the ECM beneath HUVEC monolayers appears to be accessible to solution-phase t-PA. Kinetic experiments were performed in the presence or absence of the cell monolayer to further investigate the influence of the cells on the accessibility of this population of PAI-1. If the monolayers were first removed, the t-PA-mediated decreases in ECM PAI-1 were quite rapid (Fig. 5) , with >70% of the PAI-1 in the ECM being removed within 15 min with 1 #g/ml of t-PA. Immunoblotting analysis of the supernatants from the t-PA-treated ECM revealed the presence of t-PA/PAI-1 complexes and of degraded PAI-1 (data not shown) similar to the PAI-1 profile obtained by t-PA treatment of intact HUVEC monolayers (Fig. 1 A) . The rate of PAI-1 removal from the ECM was considerably slower in the presence of cells. For example, 1 #g/ ml t-PA removed only 25 % of the PAI-1 from the ECM beneath HUVEC monolayers within 15 min, and took ,x,75 min to remove 70 % of it. Treatment of HUVEC monolayers with low concentrations of t-PA (0.25/zg/ml) only partially depleted PAI-1 from beneath the monolayers.
Effect of t-PA on the Production of PAl-1 by HUVECs
The production of PAI-1 is regulated by a wide variety ofbio- were incubated with 0.25 (o, e), 1 (t2, I), or 5 (,x, A) #g/ml t-PA in serum-free media. At the indicated times, the plates were washed and the monolayers were lysed with 0.5% Triton X-100. PAI-I associated with the ECM was then quantitated by incubation (1 h, 37°C) with affinity-purified rabbit antibodies to PAI-I followed by ~25I-goat anti-rabbit IgG. Data points represent the average of duplicates and are expressed as a percentage of control samples incubated in serum-free media in the absence of t-PA.
logically important compounds and conditions . Experiments were therefore performed to determine if the t-PA treatment itself and/or the depletion of PAI-1 from the ECM alters the rate of PAI-1 production. HUVECs were treated with t-PA for 2 h to remove PAI-1 from the ECM and then were incubated in the presence of [35S]methionine for various times. Analysis of the resulting samples by SDS-PAGE and autoradiography failed to demonstrate significant differences in the amount of PAI-1 deposited into the ECM of control and t-PA-treated HUVECs (Fig. 6 ). Immnnoprecipitation of the 35S-labeled PAIl present in the cell lysates or accumulating in the CM over this time period, confirmed these results (data not shown). Thus, t-PA treatment of HUVECs did not affect the subsequent rate of PAI-1 production.
Discussion
Biochemical studies of ECM prepared by standard techniques using nonionic or zwitterionic detergents demonstrate that PAI-1 is associated with the ECM from a variety of cultured cells. However, the extraction of cells with detergents results in an ECM preparation that may also contain a number of insoluble cellular components (Avnur and Geiger, 1981; Carter and Hakomori, 1981) . These considerations raise the possibility that PAI-I is not an integral component of the ECM, but rather a contaminating cellular component associated with insoluble surface or cytoskeletal elements. In this report, we have used procedures that do not suffer from this problem to study PAI-1 in the ECM of HUVECs. For example, the ceils were removed intact from the underlying ECM by incubation with the divalent cation chelator, EDTA. Similar quantities of PAI-1 were detected in these ECM preparations and in ECM prepared by removing HUVECs by lysis with Triton X-100 (Fig. 2) , suggesting that PAI-1 is actu- 4) , or 4 h (lanes 5 and 6) at 37°C. The cells were lysed with 0.25% Triton X-100 and the insoluble ECM extracted into SDS sample buffer. Aliquots (100 #1) of the ECM were subjected to SDS-PAGE followed by autoradiography. Positions of relative molecular mass standards are indicated.
ally present in the ECM and not a contaminating cellular component. This conclusion is supported by additional studies in which immunoelectron microscopy was used to localize PAI-1 in endothelial cells ( Fig. 4 ; Table I ). These studies demonstrate the presence of considerable PAl-l-specific immunogold particles on the cell substratum underlying the ventral cell surface of intact (nonpermeabilized) monolayers. Staining was prominent at the cell periphery suggesting that the primary and gold-conjugated secondary antibodies were able to penetrate between the regions of cell-cell contact and then bind to PAl-1 present in the ECM beneath HUVECs. Taken together, these results demonstrate that PAI-1 is present in the ECM of these cells. Recent observations suggest that it is bound, at least in part, to vitronectin also present in the ECM (Mimuro and Loskutoff, 1989a,b) . The significance of this association remains to be determined. Previous studies have suggested that PAl-1 is also present on the surface of the plasma membrane of HUVECs (Sakata et al., 1988; Barnathan et al., 1988 ). This conclusion was based on the observations that the binding of t-PA to a highaffinity binding site on HUVECs (a) required the catalytic site of t-PA, (b) was inhibited by antibodies to PAl-I, and (c) formed immunoprecipitable complexes with PAId associated with radioiodinated HUVECs (Barnathan et al., 1988) . Our data suggest that it is the PAI-1 located in the ECM beneath cultured HUVECs, and not on the cell surface, that may actually comprise this high-affinity binding site for t-PA (Hajjar et al., 1987; Barnathan et al., 1988) . For example, the PAI-1 in the ECM of confluent monolayers is clearly accessible to exogenously added tPA (Figs. 1, 2 , and 4; Table I ). Moreover, the immunoelectron microscope studies (Fig. 4 ; Table I) revealed that very little PAI-1 was actually present on the dorsal cell surface (<1% of the total detectable PAl-l). The ECM-associated PAI-1 readily forms complexes with exogenous t-PA (Fig. l) and these complexes are rapidly released into the medium when the cells are incubated at 37°C (Fig. 1) . This behavior is similar to the behavior of the t-PA/PAI-1 complexes described in the previous studies (Barnathan et al., 1988) . Thus, based on the available information, it would seem that the majority of exogenously added tPA binds to PAI-1 in the ECM and not on the cell surface. Additional studies are needed to delineate the significance of the small amount of PAI-1 actually detected on the surface (Table I) .
Kinetic analysis of the t-PA-mediated decreases in ECMassociated PAI-1 suggest that cultured HUVEC monolayers retard, but do not completely exclude, the access of various exogenous proteins to the culture substratum. The almost complete accessibility of solution-phase t-PA for PAI-1 in the ECM is not surprising, since the junctional relationships of in situ endothelium may not be preserved in vitro. In fact, these relationships may change dramatically in cultured cells since the passage of macromolecules tracers between cells is dependent on a variety of factors (Furie et al., 1984; Del Vicchio et al., 1987; Huang et al., 1988) including the culture substratum used for the growth of the cells. Thus, bovine microvascular endothelial cells grown on gelatin do not form intracellular junctions impenetrable to macromolecular tracers (i.e., tight junctions). However, when grown on a complex basement membrane (e.g., human amnion) relatively impenetrable intracellular junctions are formed similar to those present in intact blood vessels (Furie et al., 1984) . Thus, our results suggest that HUVECs grown on fibronectin-coated plastic may also lack tight junctions, a possibility that may contribute to the current confusion in the literature concerning the cellular location of PAl-1 (i.e., surface vs. ECM). It should be noted that other pathways of transport also may exist in endothelial cells (e.g., vesicles) and contribute to the accessibility of solution-phase t-PA for ECM PAI-1. In addition, the inability of low concentrations of t-PA (e.g., 0.25 #g/ml; Fig. 5 ) to efficiently deplete PAI-I from beneath the monolayers may result from the ongoing deposition of newly synthesized PAI-1 by the HUVECs.
Although the majority of ECM PAI-1 interacts with solution-phase t-PA, a variable proportion (e.g., 10-20%) was found to be non-reactive and remained associated with the ECM. Similar quantities of t-PA-resistant PAI-1 also were detected in isolated ECM preparations (Fig. 5) suggesting that the cells themselves do not interfere with this interaction. Latent PAl-1 is not cleaved by t-PA (Hekman and Loskutoff, 1985; Erickson et al., 1986) , nor does it form complexes with it (Hekman and Loskutoff, 1985; Erickson et al., 1986) , suggesting that the resistant PAI-1 may represent a small amount of the inactive inhibitor. Alternatively, the resistant inhibitor may be sterically inaccessible to solutionphase t-PA.
Endothelial cells in vivo may be exposed to a wide range of t-PA concentrations. For example, the level of t-PA in hu-man plasma is usually 1-12 ng/ml under normal conditions (Juhan-Vague et al., 1988; Prowse and MacGregor, 1988), but may increase threefold after physical exercise, venous occlusion, or infusion of 1-deamino-8-D-arginine (Juhan-Vague et al., 1988; Prowse and MacGregor, 1988) . Furthermore, the recent use of recombinant t-PA for thrombolytic therapy can result in a transient increase in plasma t-PA levels to )1/zg/ml (Loscalzo and Braunwald, 1988; Lucore and Sobel, 1988; Sobel, 1988) . Whether PAI-1 is present in the ECM of endothelium in vivo and is affected by such alterations in the plasma level of t-PA remains to be determined.
Infusion of t-PA during thrombolytic therapy frequently results in a rapid increase in circulating t-PA/PAI-1 complexes (Lucore and Sorbel, 1988) , and a small number of patients demonstrate increased plasma PAI-1 activity within 8-24 h after infusion with therapeutic doses of t-PA (Lucore and Sorbel, 1988) . The inability to demonstrate increased PAI-1 synthesis by cultured HUVECs after t-PA treatment (Fig. 6) , suggests that t-PA infusion does not directly stimulate the production of PAI-1 by endothelial cells. It should be noted, however, that PAI-1 gene expression is induced by a wide variety of substances (e.g., cytokines released by activated leukocytes, transforming growth factor ~ released by platelets, etc.) . Thus, increased PAIl production in these patients may be mediated by compounds released from cellular elements of the thrombus itself during its' degradation.
In addition to PAI-1, the ECM of endothelial cell binds several other proteins involved in blood coagulation and fibrinolysis, including plasminogen (Knudsen et al., 1986), fibronectin (Jaffe et al., 1976), and yon Willebrand factor (Hormia et al., 1983) . When the endothelial cell lining is disrupted, blood coagulation is initiated and a fibrin clot is formed in association with the subendothelial matrix. The location of active PAI-1 in the ECM may play a critical role in protecting the ECM and the ECM-associated fibrin from PA-mediated degradation through its specific inactivation of PAs. In this regard, Knudsen and Nachman (1988) demonstrated that PAI-1 associated with HUVEC ECM prevents plasmin formation and inhibits degradation of ECM preparations that are incubated with plasminogen and the t-PA secreting Bowes melanoma cell line. Thus, PAI-1 in the ECM may influence a variety of biologic events, including hemostasis, tumor invasion, and cell migration.
